Device Trial Radar · NCT05924932
Effect of HCL Insulin Delivery System on Glycemic Control in Patients With T1D
Last checked: Nov 19, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Dec 1, 2022
Primary completion
Dec 1, 2023
Study completion May 1, 2024
Sponsor
- Lead sponsor
- Masaryk Hospital Usti nad LabemAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 29, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is compare the effect of hybrid closed loop system (HCL) for automatic insulin dosing treatment on the glycemic control of type 1 diabetes (T1D) in patient with different initial glycated hemoglobin.
Conditions
- Diabetes Mellitus, Type 1
Interventions
Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6Device
type of hybrid close loop insulin delivery system
MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4Device
type of hybrid close loop insulin delivery system
Primary outcomes
What the sponsor says the trial is designed to measure.
- glycated hemoglobinTime frame: 12 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lucie Radovnická
Ústí nad Labem, Czechia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.